Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives $14.25 Consensus Target Price from Analysts

Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) have earned an average rating of “Moderate Buy” from the six research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $14.25.

Several equities research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Orchestra BioMed from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, April 21st. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th. Finally, Wall Street Zen raised shares of Orchestra BioMed from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 14th.

Insiders Place Their Bets

In other Orchestra BioMed news, insider David P. Hochman bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The shares were purchased at an average cost of $4.29 per share, with a total value of $42,900.00. Following the purchase, the insider directly owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. This represents a 0.93% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Orchestra BioMed

Several large investors have recently added to or reduced their stakes in the business. AMH Equity Ltd purchased a new stake in shares of Orchestra BioMed in the 3rd quarter valued at approximately $412,000. Cresset Asset Management LLC purchased a new stake in shares of Orchestra BioMed in the 3rd quarter valued at approximately $74,000. Qube Research & Technologies Ltd purchased a new stake in shares of Orchestra BioMed in the 3rd quarter valued at approximately $64,000. Bank of America Corp DE increased its position in shares of Orchestra BioMed by 35.7% in the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock valued at $58,000 after purchasing an additional 5,678 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Orchestra BioMed in the 4th quarter valued at approximately $57,000. 53.20% of the stock is owned by hedge funds and other institutional investors.

Orchestra BioMed Stock Performance

Shares of OBIO stock opened at $4.06 on Friday. The firm’s 50 day moving average price is $4.32 and its 200-day moving average price is $4.27. The company has a debt-to-equity ratio of 0.27, a quick ratio of 6.43 and a current ratio of 6.45. Orchestra BioMed has a one year low of $2.20 and a one year high of $5.42. The firm has a market cap of $243.11 million, a P/E ratio of -3.59 and a beta of 0.52.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.10. Orchestra BioMed had a negative net margin of 157.40% and a negative return on equity of 184.17%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. As a group, equities research analysts predict that Orchestra BioMed will post -1.68 EPS for the current year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.